Double-Blind, Randomized, Placebo-Controlled, Phase 2 Safety And Efficacy Trial Of Multistem In Adults With Ischemic Stroke
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2019
Price : $35 *
At a glance
- Drugs Allogeneic stem cell therapy Athersys (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms MASTERS-1
- Sponsors Athersys
- 14 Mar 2019 According to a Athersys media release, this study has been selected for presentation at the American Thoracic Society International Conference in May 2019.
- 20 Mar 2017 According to an Athersys media release, results from this study were published in the peer-reviewed journal, The Lancet Neurology.
- 12 Sep 2016 Results (n=126) published in an Athersys media release.